Vivos INC

Vivos Inc. reports a stock purchase and exchange agreement with a board member, leading to the elimination of Series C Preferred Stock and the issuance of Series D Preferred Stock.

Vivos Inc. has filed a Form 8-K to report the creation of Series D Convertible Preferred Stock, detailing its rights, preferences, and conversion terms.

Vivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, bolstering its leadership in targeted cancer therapies.

Vivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, strengthening its leadership in targeted cancer therapies.

Vivos Inc. announced the creation of Vivos Scientific India LLP, a wholly owned entity aimed at establishing manufacturing, expanding human therapies, and pursuing commercialization in India.

Vivos Inc. reports positive initial safety results and early signs of efficacy from its RadioGel Precision Radionuclide Therapy human clinical trials, leading to plans for trial expansion.

Vivos Inc. reports progress on FDA approvals for its RadioGel therapy and growth in its IsoPet animal division, but continues to face significant net losses and concerns about its going concern status.

Vivos Inc. reports increased revenue and strategic advancements in its precision radionuclide therapy for both human and animal oncology, alongside ongoing financing efforts.

Vivos Inc. reported increased net losses and cash burn in Q3 2025, while advancing strategic initiatives in human and animal therapies and facing FDA regulatory hurdles.

Vivos Inc. reported a wider net loss in Q2 2025 due to increased operating expenses and R&D, despite a rise in revenue, as it continues to fund its Y-90 therapy development and global expansion.

Vivos Inc. reports increased revenue for Q1 2025, driven by IsoPet therapies and clinic certifications, but continues to face significant net losses and going concern uncertainties.

Vivos Inc. reported its financial results for the third quarter of 2024, highlighting ongoing efforts in the development of its RadioGel technology and its application in both animal and human therapies.

Vivos Inc.'s 2024 annual report details ongoing efforts in developing its RadioGel technology and expanding its IsoPet veterinary services, despite facing financial challenges and expressing doubt about its ability to continue as a going concern.

Vivos Inc.'s annual report details the company's focus on its RadioGel technology for cancer treatment, progress in the veterinary market with IsoPet, and ongoing efforts to secure FDA approval for human trials.

Carlton M Cadwell, a Director and 10% owner of Vivos Inc, reported multiple transactions in common stock on October 7, 2026.

Michael K Korenko, CEO and a Director of Vivos Inc, purchased 200,000 shares of common stock on September 30, 2026 for $0.50 per share.

Brad Allan Weeks, President of Vivos Inc, purchased 25,550 shares of common stock on September 16, 2026 for $0.05 per share.

Michael K Korenko, CEO AND PRESIDENT and a Director of Vivos Inc, purchased 150,000 shares of common stock on August 10, 2026 for $0.05 per share.

Brad Allan Weeks, President of Vivos Inc, purchased 92,000 shares of common stock on July 21, 2026 for $0.05 per share.

Brad Allan Weeks, President of Vivos Inc, purchased 60,000 shares of common stock on March 31, 2026 for $0.08 per share.